SCHEMBL869669

SCHEMBL869669

C=CCc1ccccc1OCC(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 2/20 0.64
PTGDR Q13258 1/20 0.64
L3MBTL1 Q9Y468 2/20 0.59
KDM4E B2RXH2 4/20 0.56
POLB P06746 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
GLA P06280 1/20 0.53
ALDH1A1 P00352 4/20 0.52
GAA P10253 1/20 0.52
HPGD P15428 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
TBXAS1 P24557 2/20 0.49
ADRB2 P07550 3/20 0.48
ADRB1 P08588 3/20 0.48
LMNA P02545 1/20 0.48
HTR1A P08908 1/20 0.48
ADRB3 P13945 1/20 0.48
ADRA2C P18825 1/20 0.48
SLC6A2 P23975 1/20 0.48
BDKRB2 P30411 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11667153 0.87 KDM4E (0.54) PTGDR2PTGDRKDM4ESMN1; SMN2ALDH1A1
SCHEMBL7856426 0.86 PTGDR2 (0.56) PTGDR2PTGDRL3MBTL1KDM4EPOLB
SCHEMBL7857063 0.86 PTGDR2 (0.56) PTGDR2PTGDRL3MBTL1KDM4EPOLB
SCHEMBL3312441 0.85 ALDH1A1 (0.54) PTGDR2PTGDRL3MBTL1KDM4ESMN1; SMN2
SCHEMBL8088792 0.84 KDM4E (0.60) PTGDR2PTGDRKDM4EALDH1A1GAA
SCHEMBL7329095 0.83 KDM4E (0.56) PTGDR2PTGDRKDM4ESMN1; SMN2ALDH1A1
SCHEMBL10338168 0.83 KDM4E (0.60) PTGDR2PTGDRKDM4EALDH1A1GAA
SCHEMBL4209605 0.81 GAA (0.54) PTGDR2PTGDRKDM4ESMN1; SMN2ALDH1A1
SCHEMBL6633645 0.81 L3MBTL1 (0.65) PTGDR2PTGDRL3MBTL1KDM4EPOLB
SCHEMBL9016406 0.81 L3MBTL1 (0.56) PTGDR2PTGDRL3MBTL1KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240122834-A1 MEDICAMENT FOR PREVENTION AND TREATMENT OF HYPERPIGMENTATION SYMRISE AG (DE) 2024-04-18 US claimed
EP-4291154-A1 MEDICAMENT FOR PREVENTION AND TREATMENT OF HYPERPIGMENTATION Symrise AG (DE) 2023-12-20 EP claimed
EP-0520226-B2 Halogen scavenger composition ST CHEMICAL CO LTD (JP) 2000-10-11 EP claimed
US-5484610-A pH and temperature sensitive terpolymers for oral drug delivery MACROMED, INC. (US) 1996-01-16 US claimed
US-5354264-A Gas pressure driven infusion system by hydrogel electrolysis INSUTECH, INC. (US) 1994-10-11 US claimed
EP-0058605-B1 MICROEMULSION OF WATER IN A LIQUID COMBUSTIBLE SOCIETE NATIONALE ELF AQUITAINE (FR) 1986-08-27 EP claimed
JP-1113336-A None JP disclosed
JP-1113335-A None JP disclosed
JP-2258739-A None JP disclosed
JP-2188553-A None JP disclosed
US-12545851-B2 Fragrances with note of lily of the valley SYMRISE AG (DE) 2026-02-10 US disclosed
US-20250144589-A1 Method for Producing Microcapsules SYMRISE AG (DE) 2025-05-08 US disclosed
CN-116322326-B Polyurea/polyurethane microcapsules 西姆莱斯股份公司 2025-05-02 CN disclosed
JP-H02258739-A PRODUCTION OF ALKYLPHENOXYACETIC ACID MITSUBISHI PETROCHEM CO LTD 1990-10-19 JP disclosed
JP-H02188553-A PRODUCTION OF ALKYLPHENOXY ACETIC ACID MITSUBISHI PETROCHEM CO LTD 1990-07-24 JP disclosed
EP-0159864-B1 METHOD OF MODIFYING TASTE TATE & LYLE PUBLIC LIMITED COMPANY (GB) 1989-07-19 EP disclosed
JP-H01113336-A PRODUCTION OF ALKYLPHENOXYACETIC ACID MITSUBISHI PETROCHEM CO LTD 1989-05-02 JP disclosed
JP-H01113335-A PURIFICATION OF ALKYLPHENOXYACETIC ACID MITSUBISHI PETROCHEM CO LTD 1989-05-02 JP disclosed
EP-0159864-A2 Method of modifying taste TATE & LYLE PUBLIC LIMITED COMPANY (GB) 1985-10-30 EP disclosed
US-4174152-A Electrochromic devices with polymeric electrolytes AMERICAN CYANAMID COMPANY (US) 1979-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240122834-A1 MEDICAMENT FOR PREVENTION AND TREATMENT OF HYPERPIGMENTATION MC1R, OR51E2, TYR PTGDR2 348/4885PTGDR 251/4885L3MBTL1 4220/4885
US-12545851-B2 Fragrances with note of lily of the valley TRPA1, CDY1; CDY1B, TMEM109 PTGDR2 4500/4885PTGDR 4580/4885L3MBTL1 3155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.